Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABT-888
veliparib · 1 trial · 1 indication
Safety and tolerability will be assessed through clinical laboratory tests, electrocardiograms (ECGs), vital signs, physical exams and adverse event assessments
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| veliparib | DRUG | Dose orally twice daily for 7 days, consecutively, every cycle |
| Temozolomide | DRUG | Dose orally once daily for 5 days, consecutively, every cycle |
Inclusion Criteria 1. Subject has completed study participation in Study M11-846 2. Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2. 3. Subject must have adequate hematologic, renal and hepatic function per institutional normal range as follows: • Bone Marrow: Absolute neutrop...
Veliparib is an investigational small molecule drug being developed by Abbott Laboratories for solid tumor cancers. It is designed as an inhibitor of the PARP1, PARP2, and PARP3 enzymes. Veliparib has reached Phase 2 clinical development and is not approved for commercial use.
Veliparib is being studied for the treatment of solid tumor cancers. Its clinical testing has focused on use in combination with temozolomide, a chemotherapy agent, in adult patients with solid tumors. It remains an investigational therapy and is not approved for any indication.
Veliparib targets the poly(ADP-ribose) polymerase enzymes PARP1, PARP2, and PARP3. It acts as an inhibitor of these targets. PARP enzymes are involved in DNA repair processes, and inhibiting them is the basis for studying veliparib in solid tumor cancers.
Veliparib is developed by Abbott Laboratories, which trades under the ticker ABT. Abbott is the sponsor behind the clinical development program for this PARP inhibitor in solid tumor cancers.
Veliparib is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. Its development has focused on solid tumor cancers in combination with temozolomide.
Veliparib has been evaluated in the completed Phase 2 trial NCT01193140, titled a study to evaluate the safety of veliparib in combination with temozolomide in subjects with solid tumors. That trial enrolled 24 participants in the United States and has completed.